Australasian Leukaemia and Lymphoma Group
17
4
6
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
5.9%
1 terminated/withdrawn out of 17 trials
90.0%
+3.5% vs industry average
29%
5 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
Role: collaborator
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Role: collaborator
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Role: collaborator
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
Role: collaborator
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Role: collaborator
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Role: lead
Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
Role: lead
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Role: lead
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Role: lead
Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma
Role: collaborator
Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Role: collaborator
Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia
Role: collaborator
Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma
Role: collaborator
Primary Rituximab and Maintenance
Role: collaborator
Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma
Role: collaborator
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
Role: collaborator
Chemotherapy and Radiotherapy for Osteolymphoma
Role: collaborator
All 17 trials loaded